The market is expanding as a result of the rising incidence of cancer and the preference for minimally invasive medical procedures.

Changing Treatment Methods: The way cancer is treated has fundamentally changed as a result of liquid biopsy, a rapid, painless process that provides a superior alternative to invasive surgical biopsies. It helps the medical professionals discover a wealth of knowledge about the tumour through a little sample.
The non-invasiveness of liquid biopsy is the main element influencing its great demand among medical professionals. It is less invasive, more convenient, and quicker for patients than other treatments because just 5 milliliters of blood are required.

Get Our Free Sample Report: https://www.makreo.com/report/united-states-liquid-biopsy-market-revenue-and-forecast-to-2028

Industry Updates
• NeXT Liquid Biopsy, a high-performance, exomescale tumor-profiling device that uses blood samples from patients with advanced-stage solid tumour malignancy, was introduced by Personalis Inc. in 2020.
• California accounts for the major market share due to increasing number of cancer patients and increasing adoption of novel liquid biopsy tests across the cities.
• In a deal announced, LabCorp will acquire Personal Genome Diagnostics, a company providing liquid biopsy and tissue-based products and services for cancer genomics
• A merger with HH&L Acquisition Co. will result in DiaCarta becoming a public company with a pre-money equity value of USD 460 million on a fully diluted basis. The transaction is expected to close in the first quarter of 2023.
• Mesa Biotech was acquired by Thermo Fisher, which develops and commercializes PCR-based rapid point-of-care testing platforms for diagnosing diseases such as SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus.

It is anticipated that circular tumour cells will remain dominant even in the coming years. The escalating cancer rate and the development of ctDNA-based liquid biopsy analysis, which can assess prognosis and tumour progression, are driving the market demand for Circulating tumour DNA (ctDNA).

A detailed study has been conducted by Makreo Research titled “United States Liquid Biopsy Market Revenue and Forecast to 2028” that assess the present adoption rate of the newly introduced biopsy technique in the US market and also highlights future expected growth. The report identifies market trends and future opportunities for the players operating in the market. We have complied scattered information in a systematic format that has given a meaning to the market’s past performance. It is important to understand virous types of cancer present before proceeding with liquid biopsy market thus market section describes prevalence of cancer and by type of cancer.

Report covers below areas:
 Biomarkers Type (Cell-Free DNA (cfDNA) and Circulating Tumor DNA (ctDNA)
 Product (Kits & Consumables, Instruments and Services)
 Therapeutic Application (Oncology and Non-Cancer Biopsy)
 Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer and Prostate Cancer)
 Prevalence in Cities

Checkout Our Press Release: https://www.pressreleasepoint.com/united-states-liquid-biopsy-market-expected-grow-double-digit-cagr-according-makreo-research